1. Introduction {#sec1}
===============

Hematopoietic myeloproliferative neoplasms (MPN) with rearrangements of fibroblast growth factor receptor 1 (FGFR1) gene (located on chromosome 8p11) are uncommon and extremely aggressive entities. Translocations associated with this syndrome result in the fusion of the FGFR1 gene with various partners \[[@B1]\], resulting in ligand-independent FGFR activity. Patients with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene have clinical features that resemble chronic myeloid leukaemia (CML) \[[@B2], [@B3]\].

It has been reported that MPN with a t(8;22) translocation and a chimeric BCR-FGFR1 fusion gene either present or rapidly transform into an acute leukaemia \[[@B3], [@B4]\], usually refractory to currently available chemotherapeutic regimens including tyrosine kinase inhibitors (TKIs) \[[@B2], [@B5]\]. No consensus on management is available for this condition. Allogeneic hematopoietic stem-cell transplantation (HSCT) is currently the only therapeutic option in BCR-FGFR1 MPN patients \[[@B6]--[@B8]\]. Patients who lack an HLA-matched sibling might benefit from alternative donors such as HLA-haploidentical relatives.

2. Case Presentation {#sec2}
====================

We report the case of a 66-year-old man who was referred to us in January 2017 because of leukocytosis in a routine blood count. The patient was asymptomatic. On examination, there was no palpable lymphadenopathy, splenomegaly, or hepatomegaly.

Initial white blood cell (WBC) count was 36.7 × 10^9^/L, hemoglobin level 14.7 g/dl, and platelet count 600 × 10^9^/L. Peripheral blood (PB) examination showed leukocytosis with neutrophilia, metamyelocytes and myelocytes, basophilia, and no blasts. No eosinophilia and dysplasia were noted. LDH was 329 U/L (normal reference values 120--246 U/L).

A bone marrow (BM) aspirate was hypercellular with myeloid hyperplasia; myeloid/erythroid ratio was increased to 9 : 1; blast count was 0.5% per nucleated marrow cells; and mild eosinophilia was evident. BM cytogenetics showed a 46,XY,t(8;22)(p11;q11)\[19\]/46,XY\[1\]. Fluorescence in situ hybridization (FISH) with LSI FGFR1 (8p11) Dual Color Break Apart (Abbott) showed the split of one of the two fusion signals indicating a chromosome breakage in the FGFR1 locus in 90% of 200 cells analyzed ([Figure 1](#fig1){ref-type="fig"}).

BCR-FGFR1 reverse-transcriptase polymerase chain reaction was not possible to carry out.

The patient was initially managed with hydroxyurea. He was offered an hematopoietic stem-cell transplantation considering the poor prognosis of patients with t(8;22)(p11.2;q11.2). A new BM aspirate was performed 6 weeks later due to anemia which confirmed the diagnosis. Cytogenetic analysis confirmed the presence of t(8;22) as the sole aberration in all 20 metaphases analyzed.

Four months later, the patient underwent an allogeneic HSCT from an HLA-haploidentical relative (haplo-HSCT). A nonmyeloablative conditioning regimen was used (cyclophosphamide, busulfan, and fludarabine). Five × 10^6^/kg CD34 cells were infused. Initial transplant course was unremarkable. Time to neutrophils \>0.5 × 10^9^/L was 17 days, and time to platelets \>20 × 10^9^/L was 20 days. No signs or symptoms of graft-versus-host disease (GVHD) were noted.

BM exams were performed regularly after HSCT. Cytogenetic remission as well as peripheral blood full-donor chimerism was documented from day 30. At the time of this writing (more than 8 months from HSCT), the patient remained clinically well without evidence of GVHD and in cytogenetic complete remission.

3. Discussion {#sec3}
=============

Hematopoietic neoplasms with FGFR1 rearrangements are uncommon entities. Most recent WHO classification \[[@B16]\], has included them among "myeloid and lymphoid neoplasms associated with FGFR1 abnormalities (MLNAF)," which are characterized by reciprocal chromosome translocations involving FGFR1 gene located at chromosome 8p11 with a variety of fusion partner genes. One of the most frequently observed cytogenetic abnormalities is t(8;22) (p11.2;q11.2). The t(8;22) results in an in-frame fusion of FGFR1 on 8p11 and BCR on 22q11. The resultant fusion proteins activate tyrosine kinases which may result in the development of hematologic malignancies.

Patients with BCR-FGFR1 rearrangements may present with clinical and PB pictures which resemble chronic myeloid leukaemia \[[@B2], [@B4], [@B15], [@B17], [@B18]\]. The underlying BCR-FGFR1 rearrangement may thus be missed, so BM cytogenetic analysis remains the mainstay of diagnosis. In our case, cytogenetic analysis confirmed the presence of t(8;22) as the sole aberration, and no other additional chromosomal abnormalities were observed at diagnosis or during follow-up.

MLNAF may rapidly progress to CML-like blast crisis. Cases of B-acute lymphoblastic leukaemia (B-ALL), T lymphoblastic lymphoma, and acute myelogeneous leukaemia (AML) have also been reported \[[@B4], [@B9], [@B12]--[@B14], [@B19], [@B20]\].

Patients carrying the t(8;22)(p11;q11) and the subsequent BCR-FGFR1 fusion gene follow an aggressive course. There are a few reported patients who have been treated unsuccessfully with hydroxyurea \[[@B6]\], chemotherapy or TKIs \[[@B2], [@B5]\]. More potent TKIs, such as ponatinib which exhibits pan-FGFR inhibitory activity, may be of clinical benefit \[[@B10], [@B11]\]. Cardiovascular risk factors precluded the use of ponatinib in our case.

Myeloproliferative neoplasms with BCR-FGFRq rearrangement are usually refractory to chemotherapy, resulting in poor prognosis. We performed a literature search and found an additional 11 cases with BCR-FGFR1 rearrangement treated with allogeneic HSCT ([Table 1](#tab1){ref-type="table"}), and to our knowledge, this case is the first report of a patient with a BCR-FGFR1 MPN treated with haploidentical HSCT. Haploidentical donors allow patients who lack a HLA-matched one to receive a HCST with outcomes which are much like those obtained with matched donors \[[@B21]\]. HSCT may be the only therapeutic option for long-term survival at least until more efficacious TKIs become available.
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![Bone marrow: (a, b) Low magnification of the bone marrow aspirate showing myeloid hyperplasia and hypolobated megakaryocytes; (c, d) cytogenetic analysis showed a 46,XY,t(8;22)(p11;q11)\[19\]/46,XY\[1\]. Fluorescence in situ hybridization showed the split of one of the two fusion signals indicating a chromosome breakage in the FGFR1 locus; (e) low magnification of the bone marrow biopsy showing hypercellular marrow (hematoxylin and eosin); (f) reticulin stain demonstrating a mild grade of fibrosis.](CRIHEM2018-5724960.001){#fig1}

###### 

Characteristics of 12 patients with BCR-FGFR1 rearrangement treated with allo-HSTCT.

  Case   Reference                            Age (years)/sex   Diagnosis                       Donor source                      Response
  ------ ------------------------------------ ----------------- ------------------------------- --------------------------------- -----------------------------------------
  1      Present report                       65/M              MPN                             Haploidentical HSCT               CCyR
  2      Konishi et al., 2018 \[[@B8]\]       48/M              B-ALL/MPN                       Mismatched unrelated, BM          CCyR
  3      Montenegro et al., 2017 \[[@B3]\]    41/F              B-ALL/MPN                       NR                                Residual disease
  4      Wang et al., 2016 \[[@B9]\]          56/F              B-ALL/MPN                       Matched unrelated AHSCT           Remission for 5 months after AHSCT
  5      Landberg et al., 2017 \[[@B10]\]     21/M              MPN                             Mismatched unrelated AHSCT        Remission for 4 years after AHSCT
  6      Khodadoust et al., 2015 \[[@B11]\]   47/M              Trilineage mixed-phenotype AL   Matched sibling allogeneic HSCT   Residual disease
  7      Shimanuki et al., 2013 \[[@B12]\]    58/F              AL with dysplasia               Matched sibling allogeneic HSCT   Residual disease and subsequent relapse
  8      Morishige et al., 2013 \[[@B7]\]     50/M              Trilineage AL/lymphoma          Cord blood                        Remission for 2 years after AHSCT
  9      Dolan et al., 2012 \[[@B6]\]         8/M               MDS/MPN                         Unrelated AHSCT                   Remission for 4.5 years after AHSCT
  10     Haslam et al., 2012 \[[@B13]\]       21/M              B-ALL/MPN                       Mismatched, unrelated AHSCT       Residual disease
  11     Kim et al., 2011 \[[@B14]\]          59/M              Myeloid, T cell                 AHSCT                             CCyR
  12     Patnaik et al., 2010 \[[@B15]\]      57/F              MPN                             AHSCT                             Remission for 42 months after AHSCT

Abbreviations: M: male; F: female; MPN: myeloproiferative neoplasm; B-ALL: B-cell acute lymphoblastic leukaemia; CCyR: complete cytogenetic response; AL: acute leukaemia; MDS: myelodysplastic syndrome; AHSCT: allogeneic hematopoietic stem-cell transplantation; BM: bone marrow; NR: Not reported.
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